Gabriel Berger

Research

A few labs I've worked in, from writing pipelines to bench chemistry.

Alizadeh Lab · Stanford Cancer Institute

summer 2026

Visiting Student Researcher

Working on a non-invasive way to characterize Richter's transformation, the often-fatal point where chronic lymphocytic leukemia turns into an aggressive lymphoma. Cell types shed DNA and RNA into the blood differently, so measuring cell-free DNA against cell-free RNA can separate the transformed clone from the leukemia it came from.

Smith Lab · UCSF Department of Medicine

since 2025

Visiting Student Researcher

Rebuilding a high-throughput single-cell DNA and antibody sequencing pipeline (DAb-seq v2) for leukemia research, so a patient's samples can be followed across diagnosis, remission, and relapse to study treatment response and resistance. I wrote a modular C++/Python toolchain that runs on Slurm-based HPC, about 10× faster than the old one.

Bogyo Lab · Stanford University School of Medicine

2022-24

Visiting Student Researcher

Made and tested peptide-based enzyme inhibitors for drug discovery, aiming at therapeutics for Staphylococcus aureus. I built the compounds end to end (Fmoc solid-phase synthesis from phage and mRNA-display hits, purification, NMR confirmation, enzymatic assays) and co-authored a peer-reviewed paper on antimalarial proteasome inhibitors.

publications

J. M. Bennett, K. E. Ward, R. K. Muir, S. Kabeche, E. Yoo, T. Yeo, G. Lam, H. Zhang, J. Almaliti, G. Berger, F. F. Faucher, G. Lin, W. H. Gerwick, E. Yeh, D. A. Fidock, M. Bogyo. “Covalent Macrocyclic Proteasome Inhibitors Mitigate Resistance in Plasmodium falciparum.” ACS Infectious Diseases, 2023.